195 related articles for article (PubMed ID: 33996821)
21. A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer.
Liu X; Chen B; Chen J; Sun S
BMC Cancer; 2021 Mar; 21(1):335. PubMed ID: 33789615
[TBL] [Abstract][Full Text] [Related]
22. Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
Wang W; Yan L; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Front Oncol; 2020; 10():618215. PubMed ID: 33718118
[TBL] [Abstract][Full Text] [Related]
23. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.
Lu H; Zheng LY; Wu LY; Chen J; Xu N; Mi SC
Front Oncol; 2022; 12():978921. PubMed ID: 36147906
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
Front Immunol; 2022; 13():954616. PubMed ID: 35958586
[TBL] [Abstract][Full Text] [Related]
25. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
26. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
27. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications.
Feng Z; Li K; Lou J; Ma M; Wu Y; Peng C
Front Cell Dev Biol; 2021; 9():619549. PubMed ID: 33748108
[TBL] [Abstract][Full Text] [Related]
28. Derivation, Comprehensive Analysis, and Assay Validation of a Pyroptosis-Related lncRNA Prognostic Signature in Patients With Ovarian Cancer.
Cao X; Zhang Q; Zhu Y; Huo X; Bao J; Su M
Front Oncol; 2022; 12():780950. PubMed ID: 35280739
[TBL] [Abstract][Full Text] [Related]
29. Identification of a Novel Tumor Microenvironment-Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma.
Ma C; Luo H; Cao J; Zheng X; Zhang J; Zhang Y; Fu Z
Front Mol Biosci; 2020; 7():571641. PubMed ID: 33102522
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma.
Gao Y; Chen S; Vafaei S; Zhong X
Front Oncol; 2020; 10():557638. PubMed ID: 33102222
[TBL] [Abstract][Full Text] [Related]
31. Identification and Validation of EMT-Related lncRNA Prognostic Signature for Colorectal Cancer.
Li D; Lin X; Chen B; Ma Z; Zeng Y; Wang H
Front Genet; 2021; 12():723802. PubMed ID: 34659346
[No Abstract] [Full Text] [Related]
32. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
33. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
Zhang X; Zhang M; Zhang X; Zhu X; Wang J
BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
[TBL] [Abstract][Full Text] [Related]
34. Construction of a Nomogram Based on a Hypoxia-Related lncRNA Signature to Improve the Prediction of Gastric Cancer Prognosis.
Chen Q; Hu L; Chen K
Front Genet; 2020; 11():570325. PubMed ID: 33193668
[TBL] [Abstract][Full Text] [Related]
35. Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients.
Yang H; Han M; Li H
Front Oncol; 2020; 10():707. PubMed ID: 32432045
[No Abstract] [Full Text] [Related]
36. Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
Zhou Z; Yang Z; Cui Y; Lu S; Huang Y; Che X; Yang L; Zhang Y
Front Genet; 2022; 13():787884. PubMed ID: 35350243
[No Abstract] [Full Text] [Related]
37. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
39. Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma.
Dong B; Zhang Y; Gao H; Liu J; Li J
Biochem Genet; 2024 Jan; ():. PubMed ID: 38245886
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
